LTFS
RAPT

Ladenburg Thalmann Financial Services’s RAPT Therapeutics RAPT Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$0 Buy
+4
New +$736 ﹤0.01% 5467

Other funds holding RAPT

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Ladenburg Thalmann Financial Services's RAPT Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services opened a new position in RAPT Therapeutics (RAPT) in Q4 2019: 4 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #5467 among its holdings.

27 funds tracked by Wall St. Rank hold RAPT as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 4 shares of RAPT Therapeutics worth $0 as of Q4 2019.
  • RAPT Therapeutics was a new Ladenburg Thalmann Financial Services position in Q4 2019.
  • RAPT Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5467 holding.
  • 27 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.